Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Bellini trial: what clinicians have said so far
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- NCT02755597 ↗
- Completed
- AbbVie
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on Bellini yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Bellini so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Venetoclax; Bortezomib; Dexamethasone; Placebo for venetoclax
- Arms
- Venetoclax + Bortezomib and Dexamethasone · Experimental
- Placebo + Bortezomib and Dexamethasone · Placebo comparator
- Enrollment
- 291
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- AbbVie with Genentech, Inc.
- Start
- Jul 11, 2016
- Primary completion
- Mar 15, 2021
- Results posted
- Yes
- Registry record
- NCT02755597 · updated Aug 22, 2023
Publications
linked from the registry- Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Onishi M, Ku G, Pothacamury R, Jalaluddin M, Zeng J, Ross JA, Dobkowska E, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. Lancet Haematol. 2025 Aug;12(8):e574-e587. doi: 10.1016/S2352-3026(25)00139-5. Epub 2025 Jun 27. PubMed 40587991
- Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29. PubMed 33129376